This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Repligen Launches New Products In OPUS™ Line Of Pre-Packed Chromatography Columns

Stocks in this article: RGEN

Repligen Corporation (NASDAQ:RGEN) today announced the launch of its new larger-scale OPUS™ brand chromatography columns used in the manufacture of biopharmaceuticals. The OPUS™ (Open Platform User Specified) line extension is being introduced in response to rising market demand for disposable technologies in biopharmaceutical manufacturing. Such technologies are revolutionizing biomanufacturing by enabling increased facility flexibility and operating efficiencies. The new OPUS™ chromatography columns are now commercially available to biopharmaceutical manufacturers and developers worldwide.

OPUS™ pre-packed, single-use plastic chromatography columns are suitable for multi-cycle purification of biologics such as monoclonal antibodies, proteins and vaccines. The OPUS™ product line is unique in providing customers with an open platform to accommodate an unprecedented range of options in chromatography media, column sizes and bed heights. The scalability and immediate “plug-and-play” usability of OPUS™ columns increases facility flexibility and can improve the speed of process development and reduce the cost of biopharmaceutical manufacturing by decreasing the set-up, cleaning and validation times associated with traditional purification technologies.

The OPUS™ line extension broadens the utility of OPUS™ columns to the production of a wider range of clinical stage biologics and niche commercial products such as orphan biologics. The Company estimates the total chromatography market for clinical stage biologics to be approximately $100 million.

“We are pleased to introduce our larger-scale OPUS™ columns to the biomanufacturing market. As with all of the chromatography products in the OPUS™ line, these new columns are uniquely customizable, being pre-packed with media of our customers’ choosing,” said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen Corporation. “We are encouraged by the early response to the new OPUS™ products from our current customers, as well as feedback from a number of potential new customers who have been seeking process scale single-use chromatography solutions.”

Repligen acquired the initial OPUS™ technology in March 2010 as part of the Company’s ongoing commitment to leverage its core competency in bioprocessing into a broader purification product offering to the pharmaceutical industry. The Company’s bioprocessing business now sells 16 products including:

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs